Cambridge Cognition (COG) Competitors GBX 25.54 +0.54 (+2.16%) As of 08/1/2025 12:42 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock COG vs. RENX, INHC, FDBK, IQAI, TRLS, DVRG, SENS, EMIS, CRW, and INSShould you be buying Cambridge Cognition stock or one of its competitors? The main competitors of Cambridge Cognition include Renalytix (RENX), Induction Healthcare Group (INHC), Feedback (FDBK), IQ-AI (IQAI), Trellus Health (TRLS), DeepVerge (DVRG), Sensyne Health (SENS), EMIS Group (EMIS), Craneware (CRW), and Instem (INS). These companies are all part of the "health information services" industry. Cambridge Cognition vs. Its Competitors Renalytix Induction Healthcare Group Feedback IQ-AI Trellus Health DeepVerge Sensyne Health EMIS Group Craneware Instem Cambridge Cognition (LON:COG) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership. Do insiders and institutionals believe in COG or RENX? 35.2% of Cambridge Cognition shares are held by institutional investors. Comparatively, 28.4% of Renalytix shares are held by institutional investors. 29.9% of Cambridge Cognition shares are held by company insiders. Comparatively, 35.7% of Renalytix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, COG or RENX? Cambridge Cognition has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Renalytix has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500. Which has better valuation & earnings, COG or RENX? Cambridge Cognition has higher revenue and earnings than Renalytix. Cambridge Cognition is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCambridge Cognition£15.64M0.68-£1.58M-£3.76-6.79Renalytix£9.22M3.38-£109.93M-£21.19-0.36 Does the media refer more to COG or RENX? In the previous week, Cambridge Cognition's average media sentiment score of 0.00 equaled Renalytix'saverage media sentiment score. Company Overall Sentiment Cambridge Cognition Neutral Renalytix Neutral Is COG or RENX more profitable? Cambridge Cognition has a net margin of -10.07% compared to Renalytix's net margin of -1,191.75%. Renalytix's return on equity of 293.20% beat Cambridge Cognition's return on equity.Company Net Margins Return on Equity Return on Assets Cambridge Cognition-10.07% -68.83% -0.30% Renalytix -1,191.75%293.20%-93.54% SummaryCambridge Cognition beats Renalytix on 6 of the 11 factors compared between the two stocks. Get Cambridge Cognition News Delivered to You Automatically Sign up to receive the latest news and ratings for COG and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COG vs. The Competition Export to ExcelMetricCambridge CognitionHealth Information Services IndustryMedical SectorLON ExchangeMarket Cap£10.69M£222.70M£5.48B£3.03BDividend YieldN/A5.90%4.73%5.02%P/E Ratio-6.79379.8128.67176.75Price / Sales0.68223.80373.54264,362.43Price / Cash4.3147.1435.4527.97Price / Book3.515.088.274.53Net Income-£1.58M-£15.55M£3.24B£5.90B7 Day Performance-21.42%0.03%-3.69%12.55%1 Month Performance-22.61%1.48%4.33%6.07%1 Year Performance-41.15%7.55%25.95%71.57% Cambridge Cognition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COGCambridge CognitionN/AGBX 25.54+2.2%N/A-41.2%£10.69M£15.64M-6.7980Gap UpHigh Trading VolumeRENXRenalytixN/AGBX 7.13-1.7%N/A-53.8%£29.54M£9.22M-0.34102Gap DownINHCInduction Healthcare GroupN/AGBX 9.75flatN/A-8.0%£9.00M£12.57M-1.7674FDBKFeedbackN/AGBX 14.25-1.8%N/A-77.0%£6.24M£3.88M-0.5824IQAIIQ-AIN/AGBX 0.80flatN/A-33.3%£1.77M£538.19K-13.676Gap UpTRLSTrellus HealthN/AGBX 0.69+14.3%N/A-54.3%£1.33M£65.83K-0.2031Gap UpDVRGDeepVergeN/AN/AN/AN/A£1.14M£12.41M-15.0073SENSSensyne HealthN/AN/AN/AN/A£583K£7.81M-0.0270Gap DownEMISEMIS GroupN/AN/AN/AN/A£1.23B£176.86M4,085.111,560CRWCraneware1.5347 of 5 starsGBX 2,331-1.2%GBX 2,725+16.9%-0.8%£1.00B£230.77M86.12734News CoverageINSInstemN/AN/AN/AN/A£199.62M£61.63M5,928.57500News Coverage Related Companies and Tools Related Companies Renalytix Competitors Induction Healthcare Group Competitors Feedback Competitors IQ-AI Competitors Trellus Health Competitors DeepVerge Competitors Sensyne Health Competitors EMIS Group Competitors Craneware Competitors Instem Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:COG) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cambridge Cognition Holdings Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cambridge Cognition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
